Illumina and NVIDIA collaborate to decode biology and propel precision health

Key Takeaways:

• Illumina and NVIDIA form a strategic collaboration to advance genomic AI.
• The partnership focuses on enhancing multiomic data analysis and interpretation.
• Aims to accelerate drug discovery and clinical development through AI integration.
• Plans to make advanced tools accessible via Illumina Connected Analytics.
• First phase involves enabling DRAGEN algorithms on NVIDIA GPUs.

Decoding the Genome: How Illumina and NVIDIA Aim to Transform Drug Discovery

Advancing Multiomic Data Analysis for Precision Health

Illumina, Inc., a global leader in genomic sequencing and analysis, has announced a pioneering collaboration with NVIDIA to propel the analysis and interpretation of multiomic data. This partnership is poised to accelerate progress in clinical research, genomics AI development, and drug discovery, marking a significant stride in precision health.

“Over the past 20 years, Illumina has democratized sequencing, and with the progress in AI and multiomic analysis, we are enabling customers to derive novel insights for their applications,” said Rami Mehio, head of global software and informatics at Illumina. “This collaboration with NVIDIA moves us closer to that vision. This is also part of our commitment to continue to enrich our analysis and interpretation tools that will enable deeper biological insights, delivering total workflow solutions for our customers.”

The Power of Combining Sequencing and AI

The alliance brings together Illumina’s cutting-edge sequencing technologies and informatics tools with NVIDIA’s advanced AI capabilities. By optimizing the analysis of vast amounts of data involved in multiomic research, the collaboration aims to enhance drug discovery and clinical development. This integration provides powerful tools to help pharmaceutical companies identify new and better drug targets, ultimately improving patient outcomes.

“AI and data science will find their most profound application in genomics,” remarked Rory Kelleher, senior director and global head of Business Development for Healthcare and Life Sciences at NVIDIA. “Combining Illumina’s world-leading sequencing and analytics platforms with NVIDIA’s accelerated computing and AI, we will drive the next generation of genomics interpretation and democratize genomics for drug discovery through AI-powered insights.”

Accelerating Drug Discovery and Clinical Development

The partnership enables customers to leverage models developed by the NVIDIA Biology Foundation Model Research Team and partners. By integrating these models with their proprietary datasets, customers can improve performance for biologically relevant tasks, such as predicting cell states or gene transcription. This collaborative approach is set to significantly speed up the drug discovery process and enhance clinical development efforts.

Making Advanced Tools Accessible

A key objective of the collaboration is to make these sophisticated tools accessible on the Illumina Connected Analytics platform. The global research and development community stands to benefit from this accessibility, tapping into rich genomic data by integrating NVIDIA RAPIDS™ accelerated data science software with the NVIDIA BioNeMo™ platform’s generative AI models and fine-tuning capabilities. Additionally, MONAI will support spatial cell imaging workflows, expanding the potential applications of these tools.

First Phase: Enabling DRAGEN on NVIDIA GPUs

In the initial phase of their partnership, Illumina and NVIDIA will focus on enabling DRAGEN algorithms on NVIDIA GPUs. Bringing Illumina DRAGEN to NVIDIA’s accelerated computing platform will expand the accessibility of Illumina’s multiomics analysis, providing researchers and clinicians with enhanced tools to advance their work.

A Vision for the Future

This groundbreaking collaboration between Illumina and NVIDIA represents a significant leap forward in genomics and AI integration. By combining their expertise and technologies, the two companies are poised to revolutionize the field of precision health, unlocking deeper biological insights and delivering comprehensive workflow solutions to customers worldwide.

For more information on Illumina and their advancements in genomic sequencing and analysis, visit illumina.com.